Radiolabeled and native antibodies and the prospect of cure of follicular lymphoma

Details

Serval ID
serval:BIB_5C50FB8D82E7
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Radiolabeled and native antibodies and the prospect of cure of follicular lymphoma
Journal
Oncologist
Author(s)
Buchegger F., Press O. W., Delaloye Bischof A., Ketterer N.
ISSN
1083-7159
Publication state
Published
Issued date
2008
Peer-reviewed
Oui
Volume
13
Number
6
Pages
657-667
Language
english
Abstract
Advanced-stage follicular lymphoma is incurable by conventional treatment. Rituximab has been introduced in various combinations with chemotherapy and has resulted in a significantly superior treatment outcome compared with chemotherapy alone. Multiple studies have also shown the efficacy of radioimmunotherapy (RIT) both as a single agent and in combination with chemotherapy. Rituximab and RIT have clearly distinct mechanisms of action, the first acting exclusively as a biological treatment, while the second acts by a combination of biologic mechanisms and radiation effects. Despite the therapeutic efficacy of both approaches, the potential exists to further improve both modalities. Repeat administrations of RIT using appropriate radioisotopes for treatment of residual disease or new targeting strategies might afford additional benefits. Unlabeled antibody treatment could potentially benefit from the combination of antibodies directed against different target antigens or combination therapy with cytokines capable of further mobilizing patients' cellular defenses. In this review, we hypothesize that the combination of an optimized biological treatment together with radiolabeled antibodies and chemotherapy early in the disease course of advanced-stage follicular lymphoma may represent the best approach to achieve prolonged disease-free survival and eventually cure.
Keywords
Antibodies , Antibodies,Monoclonal , Antineoplastic Agents , drug therapy , Humans , Lymphoma,Follicular , methods , Patients , radiation effects , Radioimmunotherapy , radiotherapy , therapeutic use , therapy , Treatment Outcome
Pubmed
Web of science
Open Access
Yes
Create date
29/01/2009 23:13
Last modification date
20/08/2019 15:14
Usage data